Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
Depression is increasingly understood not just as a chemical imbalance but as a structural problem — a loss of synaptic connections in brain regions that regulate mood, cognition, and emotional resilience. Chronic stress and depression are associated with dendritic atrophy and reduced spine density in the prefrontal cortex and hippocampus. This has led researchers to a compelling question: can we find treatments that actually rebuild these lost connections? A groundbreaking study published in Cell Reports tested a range of psychedelic and dissociative compounds — including both psilocybin-related compounds and ketamine — for their ability to promote neural plasticity, and the results reshape how we think about these treatments.
Ly C and colleagues published their study in Cell Reports in 2018 (DOI: 10.1016/j.celrep.2018.05.022), systematically examining whether psychedelics promote structural and functional changes in neurons. Using cortical neurons from both rat and human cell lines, the researchers tested compounds spanning multiple pharmacological classes: tryptamines (including DMT and psilocin, the active metabolite of psilocybin), amphetamines (including MDMA and DOI), ergolines (including LSD), and the dissociative anesthetic ketamine.
The findings were striking in their breadth. Psychedelics across all tested classes promoted neuritogenesis (the growth of new neuronal extensions), spinogenesis (the formation of new dendritic spines, which are the physical substrates of synaptic connections), and synaptogenesis (the creation of new functional synapses). The magnitude of these effects was comparable to — and in some cases exceeded — that of BDNF, the brain's primary endogenous growth factor. DMT and LSD showed particularly robust effects on dendritic arbor complexity, while ketamine promoted significant increases in spine density.
What made this study especially valuable was the direct comparison across compound classes under controlled conditions. Ketamine and the classical psychedelics (psilocybin/psilocin, LSD, DMT) promote neuroplasticity through different primary receptors — NMDA for ketamine, 5-HT2A serotonin receptors for classical psychedelics — yet converge on similar downstream signaling pathways, particularly those involving TrkB (the BDNF receptor) and mTOR, a key regulator of protein synthesis and synaptic growth. This convergence suggests that neuroplasticity promotion may be a shared therapeutic mechanism across these otherwise pharmacologically distinct compounds.
The Ly et al. findings provide a molecular framework for understanding why both ketamine and classical psychedelics can produce rapid and sustained improvements in depression despite acting through different receptor systems. If depression involves a loss of synaptic connections, and both ketamine and psilocybin rebuild those connections — albeit through different front doors — then neuroplasticity may be the common final pathway that matters most.
This has practical implications for treatment selection. Ketamine is currently the most accessible option, available as an off-label prescription under physician supervision. Its neuroplasticity effects are well-documented and may underlie the therapeutic window that many patients describe — a period of days to weeks after treatment during which they feel more cognitively flexible, emotionally responsive, and open to change. Psilocybin, while showing comparable or potentially greater neuroplastic effects in some assays, remains a Schedule I substance and is not available outside of clinical trials in most jurisdictions.
The convergence on shared downstream pathways also opens the door to combination or sequential strategies in the future. Could ketamine-induced plasticity prepare neural circuits for more sustained remodeling through other interventions? Might sequential use of different plasticity-promoting agents produce additive or synergistic benefits? These questions remain speculative but biologically grounded.
For patients considering treatment for depression, the neuroplasticity research offers an encouraging reframe. Rather than simply adjusting neurotransmitter levels — which is how most conventional antidepressants are understood to work — ketamine and psychedelics may actually help the brain rebuild structural connections that depression has eroded. This is a fundamentally different kind of treatment effect.
If you are exploring your options, ketamine is currently the most practical entry point for neuroplasticity-based treatment. It is legally available by prescription, can be administered at home under physician supervision, and has a growing evidence base supporting its safety and efficacy. The neuroplasticity window after treatment may also be an ideal time to engage in psychotherapy, exercise, and other activities that reinforce new neural pathways.
Both ketamine and classical psychedelics like psilocybin promote structural and functional neural plasticity through overlapping downstream pathways, despite acting on different primary receptors. This shared mechanism may explain why these distinct compounds both produce rapid antidepressant effects, and it positions neuroplasticity as a central target for next-generation depression treatments.
Reference: Ly C, et al. "Psychedelics Promote Structural and Functional Neural Plasticity." Cell Reports. 2018;23(11):3170-3182. DOI: 10.1016/j.celrep.2018.05.022.
If you're considering ketamine therapy, Isha Health offers physician-led at-home treatment via telemedicine in California, New York, Texas, Florida, Colorado, Arizona, Georgia, Oregon, and Washington. No in-person visit required.
